EULAR 2023

Treatment opportunities and what is new in PsA

Pushing the brake with a new treatment strategy

Let's go for early treatment in axial envolvement?

Risk factors and prevention of arthritis

Systemic inflammation in SpA /PsA

Which is the ideal instrument to assess disease activity in axSpA?

What is early axSpA?

Secukinumab vs Adalimumab on radiographic progression in axSpA

Do NSAIDs modify the appearance of SIJ MRI?

The effect of IL-17 inhibition on radiographic progression

Should we follow chronic back pts. suspected of early axSpA?

Clinically relevant findings for SpA detection

Definition of early axSpA

Data from clinical studies relevant for daily practice

Factors associated with remission in early peripheral spondyloarthritis

Daten aus klinischen Studien für die tägliche Praxis

Definition consensuelle ASAS de la spondyloarthrite périphérique

Deberíamos seguir a los pacientes con dolor lumbar crónico con sospecha de EspAax?

Qual'e lo strumento ideale per la valutazione di attività di malattia nelle spondiloartriti?

Effekt der IL-17 Inhibition auf die Röntgenprogression

Los AINES modifican la expresión de la RM de sacrolíacas?

Was ist frühe axSpA?

Facteurs associés à l’obtention d’une rémission dans la SpA périphérique débutante

Klinisch wichtige Befunde zur SpA-Erkennung

Secukinumab vs Adalimumab dans la progression radiographique des SpA axiales

Points to consider in PsA!

Dual inhibition of IL-17A and IL-17F: a new option in PsA

Systemic inflammation objectively detectable

MTX + Biologica in PsA

No need of MTX again and again and...

Higher comorbiditiy burden in PsA vs RA

Differences between sex and gender in PsA

Early therapy in PsA is predictive

Deucravacitinib - effective and safe

Frühe Therapie bei PsA prädiktiv

Nicht schon wieder MTX...

Points to consider bei PsA

Differenze di genere nell'Artrite Psoriasi

Duale Inhibition A und F: neue Option für PsA

MTX + Biologica bei PsA

Sytemische Inflammation objektiv erkennbar

Mehr Komorbiditäten bei PsA als bei RA

Deucravacitinib - effektiv und sicher

Putting a focus on TDM

Update on JAKi safety

Keeping an eye on the lung!

Pushing the brake with a new treatment strategy

Prevention - should we treat pre-arthitis?

Peresolimab - a new therapeutic principle in rheumatology?

Preventing RA

The IL-23 pathway

Difficult to treat and poly-refractory RA in a clinical setting

Pooled safety analysis of filgotinib

Lung involvement in RA

Major adverse cardiovascular events in patients on JAK-inhibitors

What is new in RA?

Corticoid bridging in RA - useful and safe

Peresolimab - ein neues Therapieprinzip für die Rheumatologie?

AR difícil de tratar y polirrefractaria en la practica clinica

Kardiovaskulære hendelser hos pasienter behandlet med JAK-hemmere

Tratamiento con glucocorticoides al inicio del FAME - útil y segura!

Incidence of ILD in patients with RA and PsA

To stop or not to stop TNF-inhibitors after pregnancy diagnosis in women with chronic rheumatic inflammatory diseases?

Development of EMM in SpA patients treated with upadacitinib

Arthritis therapy under checkpoint-inhibition

Measurement of anti-drug antibodies in rheumatology

Immunogenicity in Adalimumab - real-world data

Overview of treatment recommendations in PsA and axSpA

Aspetti principali delle raccomandazioni per l'Artrite Psoriasica e le Spondiloartriti

Therapie der Arthritis unter Checkpoint-Inhibitoren

Insidens av interstitiell lungesykdom hos pasienter med RA og PsA

Messung von Anti-drug Antibodies in der Rheumatologie

Immunogenisitet hos pasienter behandlet med adalimumab – data fra NOR-DMARD

Interrompere o non interrompere gli anti-TNF dopo la diagnosi di gravidanza nelle donne con malattie infiammatorie reumatiche croniche?

Desarrollo de MEM en pacientes con EspA tratados con upadacitinib

Cardiovascular disease and long-term use of NSAIDs in Ankolysing Spondylitis

Childhood infections, perinatal factors, and the risk of developing Ankolysing Spondylitis

Rischio cardiovascolare e utilizzo prolungato di fans nella Spondilite anchilosante

Infezioni infantili, fattori perinatali e rischio di sviluppare spondilite anchilosante

New promising strategies in Lupus and Sjögren's Syndrome

1-year data on CAR-T cell therapy in lupus

Update on CAR-T cells!

JAK inhibition and BTK-JAK inhibition in lupus

Telitacicept in lupus

1-Jahres Daten zur CAR-T-Zell Therapie beim Lupus

Aktuelles zur CAR-T-Zelltherapie!

JAK-Inhibition und BTK-JAK-Inhibition bei Lupus

Telitacicept beim Lupus

Telitacicept in Sjögren's Syndrome

Telitacicept beim Sjögren Syndrom

COVID-19: a pandemic with a long tail

IL-17 isoforms in enthesitis

IL-17-Isoformen bei Enthesitis